Paritaprevir - monotherapy

Drug Profile

Paritaprevir - monotherapy

Alternative Names: ABT-450; Veruprevir; Veruprevir anhydrous

Latest Information Update: 29 Jun 2015

Price : $50

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer Abbott Laboratories; Enanta Pharmaceuticals
  • Class Antivirals; Aza compounds; Cyclopropanes; Phenanthridines; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Jun 2010 Abbott completes a phase I trial in healthy volunteers in USA
  • 03 Mar 2010 Phase-II clinical trials in Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top